Aethlon Medical Inc (AEMD) — SEC Filings
Aethlon Medical Inc (AEMD) — 38 SEC filings. Latest: 8-K (Dec 8, 2025). Includes 23 8-K, 6 10-Q, 3 S-1/A.
View Aethlon Medical Inc on SEC EDGAR
Overview
Aethlon Medical Inc (AEMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Aethlon Medical, Inc. (AEMD) reported a net loss of $3,248,958 for the six months ended September 30, 2025, a significant improvement from the $5,378,414 net loss in the same period of 2024. Total operating expenses decreased substantially to $3,302,220 for the six months ended September 30, 2025, d
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 3 bearish, 32 neutral, 3 mixed. The dominant filing sentiment for Aethlon Medical Inc is neutral.
Filing Type Overview
Aethlon Medical Inc (AEMD) has filed 23 8-K, 6 10-Q, 3 S-1/A, 2 S-1, 2 10-K, 1 DEF 14A, 1 10-K/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of AEMD's 37 recent filings, 6 were flagged as high-risk, 17 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$3,248,958 |
| EPS | -$10.65 |
| Debt-to-Equity | 0.27 |
| Cash Position | $5,853,493 |
| Operating Margin | N/A |
| Total Assets | $7,323,090 |
| Total Debt | $1,577,113 |
Key Executives
- James B. Frakes
- Dennis Doucette, Esq.
- M. Ali Panjwani
- Thomas E. Colvin
- Kevin R. Richardson
Industry Context
Aethlon Medical operates in the highly competitive and innovation-driven biotechnology sector, focusing on novel therapeutic devices. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies like Aethlon often rely on breakthrough technologies and strategic partnerships to advance their pipelines and secure market share.
Top Tags
8-k (7) · medical-devices (5) · Clinical Trials (4) · Public Offering (4) · 8-K (4) · filing (4) · financials (4) · Aethlon Medical (4) · Biotechnology (3) · Medical Devices (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $3,248,958 | for the six months ended September 30, 2025, a decrease from $5,378,414 in 2024 |
| Cash and Cash Equivalents | $5,853,493 | as of September 30, 2025, up from $5,501,261 at March 31, 2025 |
| Proceeds from Common Stock Issuance | $3,744,466 | net cash provided by financing activities for the six months ended September 30, 2025 |
| Common Shares Outstanding | 761,318 | as of November 10, 2025 |
| Reverse Stock Split Ratio | 1-for-10 | implemented on October 16, 2025, to address Nasdaq compliance |
| Accumulated Deficit | $171,203,775 | as of September 30, 2025, indicating significant historical losses |
| Participants Treated | 3 | in the first cohort of the Phase 1 oncology trial in Australia as of November 3, 2025 |
| Total Operating Expenses | $3,302,220 | for the six months ended September 30, 2025, down from $5,521,856 in 2024 |
| Stock-based Compensation | $144,884 | for the six months ended September 30, 2025, a decrease from $252,821 in 2024 |
| Combined public offering price per share and accompanying warrant | $2.19 | Fixed price for the duration of the Company Offering |
| Maximum shares of common stock and accompanying warrants offered | 4,566,210 | Represents the total number of securities Aethlon is offering in the Company Offering |
| Shares of common stock offered by selling securityholders | 1,550,000 | Issuable upon exercise of outstanding inducement warrants from a March 16, 2025 private placement |
| Cash fee payable to placement agent | 6.25% | Percentage of aggregate gross proceeds raised at closing of the offering |
| Placement agent warrants | 4.0% | Percentage of total shares of common stock issued in the offering, exercisable by Maxim Group LLC |
| Par value per share of common stock | $0.001 | Also the exercise price for pre-funded warrants |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Aethlon Medical Inc (AEMD)?
Aethlon Medical Inc has 38 recent SEC filings from Feb 2024 to Dec 2025, including 23 8-K, 6 10-Q, 3 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AEMD filings?
Across 38 filings, the sentiment breakdown is: 3 bearish, 32 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Aethlon Medical Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Aethlon Medical Inc (AEMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Aethlon Medical Inc?
Key financial highlights from Aethlon Medical Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AEMD?
The investment thesis for AEMD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Aethlon Medical Inc?
Key executives identified across Aethlon Medical Inc's filings include James B. Frakes, Dennis Doucette, Esq., M. Ali Panjwani, Thomas E. Colvin, Kevin R. Richardson.
What are the main risk factors for Aethlon Medical Inc stock?
Of AEMD's 37 assessed filings, 6 were flagged high-risk, 17 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Aethlon Medical Inc?
Forward guidance and predictions for Aethlon Medical Inc are extracted from SEC filings as they are enriched.